Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) GI

Jun 29
- Jul 2, 2022
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.
Bullock, et al.

Filter by

Search
Generic filters
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Clinical Cancer Research

Jul 1, 2022
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny B, et al.
AGEN1571 (ILT2 Antagonist)

American Association for Cancer Research (AACR)

Apr 8
- Apr 12, 2022
AGEN1571 is a novel high-affinity ILT2 antagonist antibody that promotes adaptive and innate immune responses.
Udartseva, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)

Journal of Clinical Oncology

Dec 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O’Malley, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)

Society for Immunotherapy of Cancer (SITC)

Nov 10
- Nov 14, 2021
Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product.
Purbhoo, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)

Society for Immunotherapy of Cancer (SITC)

Nov 10
- Nov 14, 2021
AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models.
Yigit, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)

Society for Immunotherapy of Cancer (SITC)

Nov 10
- Nov 14, 2021
Identification and characterization of an allogeneic iNKT-CAR targeting BCMA.
Michelet, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 10
- Nov 14, 2021
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results.
El-Khoueiry, et al.
MK-4830 (ILT4 Antagonist)

Clinical Cancer Research

Oct 1, 2021
First-in-Class Anti-immunoglobulin – like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu, et al.
Zalifrelimab (CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Balstilimab (PD-1 Antagonist)

Gynecologic Oncology

Aug 25, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)

Future Oncology

Aug 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

American Society of Clinical Oncology (ASCO)

Jun 3
- Jun 7, 2021
Differentiated Activity Profile for the PD-1 Inhibitor Balstilimab.
C.Joyce, et al.
AGEN2373 (CD137 Agonist)

American Society of Clinical Oncology (ASCO)

Jun 3
- Jun 7, 2021
Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors.
Tolcher, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR)

Apr 9
- Apr 14, 2021
Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors.
Tanne, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR)

Apr 9
- Apr 14, 2021
Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab.
Shapiro, et al.
Balstilimab (PD-1 Antagonist)

SGO 2021 Virtual Annual Meetings on Women’s Cancer Abstracts

Mar 19
- Mar 22, 2021
RaPiDS (GOG-3028): A Randomized Phase II Studyof Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

Oncogene

Jan 26, 2021
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.
Grossman, et al.
AGEN2373 (CD137 Agonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects.
Galand, et al.
Zalifrelimab (CTLA-4 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer.
O’Malley, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing.
Burcu, et al.
Zalifrelimab (CTLA-4 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822).
Perez, et al.
AGEN1327 (TIGIT Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity.
Ward, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy.
O’Day, et al.
VISION

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro.
Pabla, et al.
Zalifrelimab (CTLA-4 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials .
O’Malley, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR)

Jun 22
- Jun 24, 2020
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors.
Tanne, et al.